Company profile: Hyloris Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical therapies, including Sotalol IV for atrial fibrillation (developed with AltaThera), Maxigesic IV, a non-opioid analgesic for post-operative pain combining paracetamol and ibuprofen sodium dihydrate (developed with AFT Pharmaceuticals), and Podofilox Gel 0.5% for anogenital warts, equivalent to Condylox.
Products and services
- Maxigesic IV: A non-opioid analgesic combining paracetamol and ibuprofen sodium dihydrate for post-operative pain management, developed with AFT Pharmaceuticals, delivering dual-mechanism relief
- Podofilox Gel 0.5%: A topical 0.5% formulation for treating anogenital warts, equivalent to Condylox, enabling targeted lesion application and localized therapy
- Sotalol IV: An intravenous formulation used for the treatment of atrial fibrillation, developed in collaboration with AltaThera, enabling IV dosing.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hyloris Pharmaceuticals
Truvic Medical
HQ: United States
Website
- Description: Provider of devices for single-session thrombus removal without thrombolytics, including Symphony, a device that uses continuous aspiration and mechanical assistance to engage and disrupt clots, and Prodigy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Truvic Medical company profile →
CardioGenics
HQ: Turkey
Website
- Description: Provider of sensitive diagnostic test products to the IVD market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CardioGenics company profile →
Tenaya Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage gene and small molecule therapies for heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, an HDAC6 inhibitor for heart failure with preserved ejection fraction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tenaya Therapeutics company profile →
Insightra
HQ: United States
Website
- Description: Provider of medical devices focused on hernia and other surgical therapies, including the Ultra 7Fr Intra-Aortic Balloon Catheter for cardiovascular interventions, offering a smaller 7Fr diameter with performance comparable to an 8Fr catheter, suitable for patients with reduced vessel size.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insightra company profile →
CiVi Biopharma
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development focused on novel cardiovascular therapies, including CiVi 008, an oral PCSK9-targeting treatment to lower LDL cholesterol and prevent atherosclerotic cardiovascular disease, and CiVi 030, an intravenous iloprost formulation for severe frostbite with vasodilator, platelet inhibitor, anti-inflammatory, and anti-fibrotic effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CiVi Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hyloris Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hyloris Pharmaceuticals
2.2 - Growth funds investing in similar companies to Hyloris Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hyloris Pharmaceuticals
4.2 - Public trading comparable groups for Hyloris Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →